MarketBeat Compares Aterian and Zepp Health Financial Profiles
What happened
MarketBeat provided a comparison of Aterian and Zepp Health, noting both are small-cap consumer discretionary companies. The comparison covered metrics such as net margins, return on equity, institutional ownership, and stock volatility. Aterian has higher earnings but lower revenue than Zepp Health, which is trading at a lower price-to-earnings ratio than Aterian.
From dailypolitical.com
Why it matters
The analysis details differences in risk and ownership structure between the two companies. For instance, Zepp Health has significantly higher institutional ownership (52.6%) compared to Aterian (7.0%), while Zepp Health also exhibits higher stock price volatility (Beta of 1.8) than Aterian (Beta of 1.2).
From dailypolitical.com
Who's involved
- MarketBeatProvided the comparative analysis and analyst recommendations for the companies.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- NasdaqSpeculative
Investors might adjust their investment decisions based on the differing risk and valuation profiles of the two companies listed on the exchange.
Keep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
North America
continent in the Americas
Related events
- MarketBeat is providing analyst ratings for Zynex, and SenesTech is headquartered in Phoenix, Arizona.
- MarketBeat provided analyst recommendations and compared Organon & Co. and Xeris Biopharma.
- Abbott Laboratories was featured as one of five stocks to watch on MarketBeat on May 26, 2026.
- MarketBeat reported analyst recommendations for small-cap finance companies Perella Weinberg Partners and Fidus Investment.
- MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.